News Image

Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.

By Mill Chart

Last update: May 9, 2024

Growth investors are on the lookout for stocks displaying robust revenue and EPS growth. In this analysis, we'll assess whether CORCEPT THERAPEUTICS INC (NASDAQ:CORT) aligns with growth investing criteria, especially as it consolidates and signals a possible breakout. As always, investors should conduct their own research, but CORCEPT THERAPEUTICS INC has surfaced on our radar for growth with base formation, warranting further examination.

Exploring NASDAQ:CORT's Growth

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:CORT has earned a 8 for growth:

  • The Earnings Per Share has grown by an impressive 29.27% over the past year.
  • CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.48%.
  • Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 13.94% on average per year.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 28.00% on average per year.
  • CORT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.69% yearly.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Looking at the Health

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:CORT has achieved a 9 out of 10:

  • An Altman-Z score of 17.72 indicates that CORT is not in any danger for bankruptcy at the moment.
  • CORT's Altman-Z score of 17.72 is amongst the best of the industry. CORT outperforms 91.79% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • CORT has a Current Ratio of 5.18. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.18, CORT is in the better half of the industry, outperforming 67.18% of the companies in the same industry.
  • CORT has a Quick Ratio of 5.10. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • CORT has a Quick ratio of 5.10. This is in the better half of the industry: CORT outperforms 67.69% of its industry peers.

A Closer Look at Profitability for NASDAQ:CORT

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NASDAQ:CORT was assigned a score of 8 for profitability:

  • CORT's Return On Assets of 17.99% is amongst the best of the industry. CORT outperforms 97.44% of its industry peers.
  • CORT's Return On Equity of 21.54% is amongst the best of the industry. CORT outperforms 93.33% of its industry peers.
  • CORT has a better Return On Invested Capital (18.83%) than 95.38% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CORT is significantly above the industry average of 16.49%.
  • The Profit Margin of CORT (22.54%) is better than 94.36% of its industry peers.
  • CORT's Operating Margin of 23.30% is amongst the best of the industry. CORT outperforms 91.28% of its industry peers.
  • The Gross Margin of CORT (98.55%) is better than 99.49% of its industry peers.

How does the Setup look for NASDAQ:CORT

Besides the Technical Rating, ChartMill also assign a Setup Rating to every stock. This setup score also ranges from 0 to 10 and determines to which extend the stock is consolidating. This is achieved by evaluating multiple short term technical indicators. NASDAQ:CORT currently has a 7 as setup rating:

Although the technical rating is only medium, CORT does present a nice setup opportunity. Prices have been consolidating lately. There is a resistance zone just above the current price starting at 25.41. Right above this resistance zone may be a good entry point. We notice that large players showed an interest for CORT in the last couple of days, which is a good sign.

More Strong Growth stocks can be found in our Strong Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of CORT

Check the latest full technical report of CORT for a complete technical analysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (5/17/2024, 7:00:01 PM)

After market: 28.09 0 (0%)

28.09

+0.55 (+2%)

CORT News

News Image10 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.

News Image10 days ago - Market News VideoCorcept Therapeutics Breaks Above 200-Day Moving Average - Bullish for CORT
News Image11 days ago - ChartmillExploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.

Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.

News Image18 days ago - Market News VideoNotable Thursday Option Activity: PCT, AUPH, CORT
News Image18 days ago - InvestorPlaceCORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024

CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image18 days ago - BusinessInsiderCORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corcept Therapeutics (NASDAQ:CORT) just reported results for the first quarter ...

News Image19 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
News Image19 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024.

News Image21 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 4 CATALYST Trial
News Image26 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
News Image26 days ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...

News Imagea month ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
CORT Links
Follow us for more